| Literature DB >> 32326658 |
Anna Baldisserotto1, Monica Demurtas2, Ilaria Lampronti3, Massimo Tacchini4, Davide Moi2, Gianfranco Balboni2, Silvia Vertuani1, Stefano Manfredini1, Valentina Onnis2.
Abstract
In the search of multifunctional compounds we designed benzimidazole derivatives endowed with phenolic hydroxy groups and a hydrazone moiety as potential radical-scavenger and the antioxidant agents. The target molecules have been prepared by a simple synthetic procedure and tested for their antioxidant activity by DPPH, FRAP, and ORAC test, for photoprotective activity against UV rays and for antiproliferative activity against Colo-38 melanoma cells. Furthermore, two different dermocosmetic formulations were prepared with the compounds endowed with the best antioxidant and photoprotective profile and their release from formulation evaluated using Franz Cells system. High antioxidant activity is related to the presence of at least two hydroxy groups on arylidene moiety of benzimidazoles. Structure activity analysis revealed that the position of hydroxy groups is crucial for antioxidant activity as well as the presence of a 2-hydroxy-4-(diethylamino)arylidene group. The same correlation pattern was found to be related to photoprotective activity resulting in an UVA Protection Factor better than the commercial solar filter PBSA and antiproliferative activity against melanoma cells without producing cytotoxicity on normal keratinocytes. The release analysis indicated that high antioxidant activities are achieved with limited release at concentration compatible with the use as UV sunscreen filter.Entities:
Keywords: antioxidant activity; antiproliferative activity; benzimidazoles; hydrazones; photoprotective agents; polyhydroxylated compounds
Year: 2020 PMID: 32326658 PMCID: PMC7243105 DOI: 10.3390/ph13040068
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Antioxidant activity of N1-(4-arylidene)-1H-benzo[d]imidazole-2-carbohydrazides 3–15.
|
| ||||
|---|---|---|---|---|
| Compound | Aryl | DPPH a | FRAP a | ORAC a |
|
| 4379.0 ± 9.8 | 6872.6 ± 9.7 | 15,906.4 ± 14.2 | |
|
| 2-OH-phenyl | <23.2 b | 48.0 ± 2.6 | - |
|
| 3-OH-phenyl | <13.0 b | 1023.3 ± 9.4 | 21,808.0 ± 99.1 |
|
| 4-OH-phenyl | 29.6 ± 0.1 | 1040.1 ± 11.2 | 30,911.3± 36.4 |
|
| 2,4-(OH)2-phenyl | 200.6 ± 1.5 | 286.7 ± 10.3 | 9296.8 ± 72.3 |
|
| 2,5-(OH)2-phenyl | 9387.9 ± 13.8 | 5330.6 ± 29.6 | 17,856.9 ± 35.1 |
|
| 2,3,4-(OH)3-phenyl | 10,945.2 ± 38.5 | 10,064.6 ± 24.6 | 4221.5 ± 10.5 |
|
| 2,4,6-(OH)3-phenyl | 192.6 ± 3.5 | 4071.7 ± 10.0 | 4098.6 ± 39.1 |
|
| 2-OH-4-OMe-phenyl | 201.2 ± 4.9 | 231.9 ± 5.5 | - |
|
| 2-OH-3-OEt-phenyl | 38.1 ± 1.6 | 104.5 ± 2.1 | - |
|
| 3-OH-4-OMe-phenyl | 171.5 ± 6.1 | 3418.8 ± 15.2 | 17,170.7 ± 18.4 |
|
| 2-OH-4-N(Et)2-phenyl | 1065.0 ± 5.9 | 3525.4 ± 13.4 | 754.4 ± 19.0 |
|
| 2-OH-5-Cl-phenyl | << 13.29 b | 54.8 ± 1.3 | - |
|
| 2-OH-5-Br-phenyl | 28.8 ± 1.2 | 81.7 ±2.7 | - |
a Each value was obtained from three experiments (mean ± SE);—not tested. b LOQ limit of quantification;—not tested.
In solution UV-filtering activity of selected hydrazones.
| Compound | SPF | UVA/UVB | UVAPF0 | λc (nm) |
|---|---|---|---|---|
|
| 3.42 | 0.29 | 1.04 | 322 |
|
| 11.54 | 0.27 | 1.60 | 343 |
|
| 12.32 | 0.75 | 2.95 | 353 |
|
| 4.81 | 1.26 | 4.84 | 366 |
|
| 11.23 | 0.32 | 3.24 | 377 |
|
| 8.12 | 2.23 | 6.79 | 366 |
|
| 8.34 | 2.27 | 10.65 | 370 |
|
| 8.95 | 1.13 | 3.60 | 358 |
|
| 1.57 | 1.18 | 3.99 | 394 |
Figure 1Panel (a), UV spectra of the reference PBSA; panel (b), UV absorption spectra of hydrazone derivatives: 4 (light blue), 5 (violet), 6 (dark green), 7 (red), 8 (blue), 9 (light green), 12 (orange), 13 (fuchsia).
Figure 2Permeation profiles of Oxisol (panel (a)), and hydrazones 9 (panel (b)) and 13 (panel (c)). Line green corresponds to formulation A (optimized for skin adsorption), line yellow corresponds to Formulation B (optimized to best solubilize the active in formula).
Effects of selected hydrazone derivatives on the proliferation of melanoma Colo-38 and keratinocyte Ha-Cat human cell lines.
| Compound | IC50 (μM) | Compound | IC50 (μM) | |
|---|---|---|---|---|
| Colo-38 | Colo-38 | Ha-Cat | ||
|
| 362.63 ± 15.05 |
| 46.6 2 ± 3.57 | |
|
| 216.16 ± 40.21 |
| 459.59 ± 103.87 | |
|
| 46.62 ± 0.82 |
| 0.84 ± 0.03 | 53.16 ± 4.33 |
|
| 35.49 ± 0.42 |
| 0.50 ± 0.12 | 5.03 ± 0.76 |